Cure My Disease

Don't miss your cure!

 Log in / Sign up

New asthma drug aims to cut severe attacks in half

NCT ID NCT07372287

Recruiting now Disease control Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 3 trial tests an injectable drug called CM326 in 230 adults with moderate to severe asthma. The goal is to see if it can reduce the number of severe asthma attacks over one year. Participants will receive either CM326 or a placebo, and researchers will also measure changes in lung function and safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CM326 (injectable drug)
What this could lead to
If successful, this could provide a new treatment option to reduce severe asthma attacks and improve lung function for people with moderate to severe asthma.
What could go wrong
This is a Phase 3 trial, but results are not guaranteed. The drug may not work better than placebo, and side effects are possible. It is not a cure, and patients will still need ongoing asthma management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE-TO-SEVERE ASTHMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ruijin Hospital, Shanghai Jiao tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, 200000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.